Meeting
2015 ASCO Annual Meeting
Effectiveness of targeting HER2 in heavily pretreated patients with occult HER2-positive (tissue-negative, serum-positive and/or HER2-positive circulating tumor cells) metastatic breast cancer in the clinical routine.
Authors
Christian M. Kurbacher
Gynecologic Center Bonn-Friedensplatz, Bonn, Germany
Christian M. Kurbacher , Annegret Quade , Gerhard Kunstmann , Susanne Herz , Jutta A. Kurbacher , Mathias A. Warm
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—HER2/ER
Track
Breast Cancer
Sub Track
HER2+
Citation
J Clin Oncol 33, 2015 (suppl; abstr 591)
DOI
10.1200/jco.2015.33.15_suppl.591
Abstract #
591
Poster Bd #
80
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
Anti-HER2 treatment in advanced metastatic HER2-negative breast cancer patients with elevated serum levels of the HER2 extracellular domain and/or HER2 overexpressing circulating tumor cells.
First Author: Christian M. Kurbacher
Poster
2015 ASCO Annual Meeting
Correlation of trastuzumab treatment benefit with quantitative HER2 expression levels in HER2 positive metastatic breast cancer.
First Author: Beatrice Bachmeier
Poster
2014 ASCO Annual Meeting
Effect of serum HER2, TIMP-1, and CAIX on outcome in HER2+ metastatic breast cancer patients treated in first line with lapatinib or trastuzumab combined with taxane: NCIC CTG MA.31.
First Author: Diep Ho
Poster
2012 ASCO Annual Meeting
Impact of adjuvant trastuzumab on outcomes of HER2-positive breast cancer patients treated with HER2-targeted therapy in the metastatic setting.
First Author: Rashmi Krishna Murthy